Figure 5.

The administration of XE-991 reverses the inhibition of the mechanical allodynia and grip strength deficits of A-ITC and P-ITC during chronic osteoarthritis pain. The mechanical allodynia in the ipsilateral paw (A) and grip strength deficits in the hind paws (B) of the MIA-injected mice treated with A-ITC or P-ITC during 4 or 10 days alone and combined with the selective Kv7 potassium channel blocker XE-991 are shown. The effects of XE-991 administered alone are also represented. For each test evaluated, * denotes significant differences vs. saline-saline-injected mice treated with vehicle and + denotes significant differences vs. MIA saline-injected mice treated with a drug (p < 0.05; one-way ANOVA followed by the Student–Newman–Keuls test). The results are shown as the mean values ± SEM; n = 6 animals per experimental group.